In a significant move towards bolstering its oncology portfolio, Novartis has agreed to acquire MorphoSys for €68 per share, reflecting an enterprise value of approximately US$2.9 B (€2.7 B). The acquisition is centered on MorphoSys’ pelabresib (CPI-0610), a late-stage candidate for myelofibrosis (MF) and tulmimetostat (CPI-0209), an early-stage investigational therapeutic for solid tumours or lymphomas. This acquisition represents a strategic move by Novartis to diversify its therapeutic offerings and further strengthen its leading pipeline and portfolio in oncology, while also enhancing its global footprint in haematology.